Gene expression profiling in a validation cohort of locally advanced and recurrent/metastatic salivary gland cancers: the INDAGA-UK trial

Salivary gland cancers are being genetically mapped in a UK-wide trial to find the abnormal genes driving these rare tumours and identify potential new drug targets. This matters because when salivary gland cancers recur or spread to other parts of the body, effective treatment options are lacking. The diseases are rare and poorly understood at the molecular level, so doctors have few clues about which drugs might work or why some tumours behave more aggressively than others. The trial will analyse tumour tissue already collected during routine care, stored in a biobank, and link that genetic information to patients’ medical and surgical histories. If the research succeeds, it could reveal which genes are consistently abnormal across different salivary gland cancers, giving clinicians a clearer picture of cancer behaviour and pointing toward existing drugs—or new ones—that might target those specific genetic faults. The study is a first step: it aims to describe the genetic landscape, not yet to test treatments. But similar gene-profiling efforts in other cancers have led directly to targeted therapies that improve survival.